The Limb Preservation Foundation
The Limb Preservation Foundation
CBS News Program TONIGHT at 5:30 p.m.
The CBS Evening News will feature a story on today's broadcast (April 18
at 5:30 MST) about the collaborative efforts between Dr. Ross Wilkins of
the Denver Clinic for Extremities at Risk, and Dr. Stephen Withrow of
the Colorado State University Animal Cancer Center, and their efforts to
find the cause and the cure for bone cancer and other extremity diseases.
The April 18 news story will be entitled "A Tale of Two Doctors" and
will feature interviews with both doctors and information on their
research collaborations in regard to osteosarcoma. Drs. Wilkins and
Withrow have been working together for many years on collaborative
research pertaining to osteosarcoma treatments and protocols for
patients with limb cancer.
Thanks to their joint efforts, the survival rate of pediatric limb
cancer patients has increased from 60% in 1986 to 92% today. The Limb
Preservation Foundation is committed to the research being conducted by
these two doctors and is working to continue their efforts through the
development of a Limb Preservation University Chair in support of
research in Musculoskeletal Biology at the CSU Animal Cancer Center in
Fort Collins. The Foundation will be working with CSU to jointly fund
this research position with the goal of raising $3,000,000 together in
the next three years.
Dr. Ross Wilkins is Founder of The Limb Preservation Foundation and
Medical Director of the Denver Clinic for Extremities at Risk.
Dr. Stephen Withrow is the Director of the CSU Animal Cancer Center and
holds a seat on the Board of Directors of The Limb Preservation
Foundation. The Limb Preservation Foundation is a charitable
organization that was established in 1987. The mission of the Foundation
is to support the prevention and treatment of limb threatening
conditions due to trauma, tumor or infection.
The Foundation coordinates and funds patient treatment programs,
educational programs and research with the goal of addressing the needs
of individuals who are facing the potential loss of a limb.
Category: Events and Coming Attractions
Submitted: Tuesday, April 18, 2006
Subject: ACC
Contact: Lynda J Reed
Phone: (970) 297-4175

Total tibial endoprosthesis including ankle joint and knee joint replacement in a patient with Ewing sarcoma

Total tibial endoprosthesis including ankle joint and knee
joint replacement in a patient with Ewing sarcoma

To read this go to:

Georg Gosheger, Jendrik Hardes, Benedikt Leidinger, Carsten Gebert,
Helmut Ahrens, Winfried Winkelmann
and Christian Goetze

Department of Orthopaedics, University of Muenster, Germany
Correspondance GG:
Submitted 04-07-23. Accepted 05-01-09

Surgical options and outcomes in bone sarcoma.

Expert Rev Anticancer Ther. 2006 Feb;6(2):239-48.  

Surgical options and outcomes in bone sarcoma.

Wafa H, Grimer RJ.

The Royal Orthopaedic Hospital NHS Trust, Bristol Road South,
Northfield, Birmingham, B31 2AP, UK.

Bone sarcomas are challenging to treat. The primary goal of treatment
is local control of the disease while, if possible, achieving salvage
of the limb and its function. There is no ideal method of
reconstruction in limb-salvage surgery but the choice of the method of
reconstruction should be individualized based upon many factors
including the patient's age, the extent and location of the tumor, the
wishes of the patient, and the availability of surgical facilities and
expertise, as well as the cost of the procedure. In this review, the
authors explore the advantages and disadvantages of the different
methods of limb reconstruction. The surgical management of bone
sarcomas is a real challenge to the orthopedic surgeon, owing to the
diversity of sites in which tumors arise, combined with the extension
of the tumor into adjacent soft tissues and their proximity, in many
cases, to major neurovascular structures. There have been dramatic
improvements in survival for patients with osteosarcoma and Ewing's
sarcoma in the past 30 years owing to increasing effectiveness of
chemotherapy. This, along with developments in imaging techniques
(magnetic resonance imaging in particular) has led to earlier diagnosis
and more accurate preoperative staging. Whilst traditional treatment
for bone tumors used to be amputation, advances in surgical techniques
have made limb-salvage procedures a valid alternative method of
treatment to amputation in 80-85% of patients with primary bone

PMID: 16445376 [PubMed – in process]

Osteotech Receives Its First Grafton(R) DBM 510(k) FDA Clearance Bone Graft Paste

Osteotech Receives Its First Grafton(R) DBM 510(k) FDA Clearance Bone
Graft Paste

EATONTOWN, N.J., Nov. 29 /PRNewswire-FirstCall/ — Osteotech, Inc.
(Nasdaq: OSTE) announced today that the Food and Drug Administration
has cleared its 510(k) for Grafton Plus(R) DBM Paste for use as a bone
extender, bone graft substitute and bone void filler in orthopedic
    Sam Owusu-Akyaw, Osteotech's President and Chief Operating Officer,
stated, “The Grafton Plus(R) DBM Paste 510(k) for orthopedic use is the
of five previously reported 510(k) applications that the Company has
with the FDA covering its family of Grafton(R) DBM products.  We are
particularly pleased that this 510(k) application has been cleared for
all the
indications for which we applied.  To our knowledge, this is the only
product on the market to receive clearance as a bone graft extender,
graft substitute and bone void filler.”
    Mr. Owusu-Akyaw concluded, “We look forward to the FDA clearing, in
near future, the remaining four 510(k) applications covering our
DBM family of products.  We have been working diligently with the FDA
reviewers on all of our 510(k) applications and we believe that they
receive clearance by the Agency.”
    Grafton Plus(R) DBM Paste is a demineralized bone product that has
proven to be osteoinductive in an athymic rat in vivo model as well as
osteoconductive.  Further, results of bone formation studies in animals
that Grafton Plus(R) DBM Paste performed comparably to autograft. 
Plus(R) DBM is prepared utilizing a proprietary processing method that
been validated to consistently produce DBM that is osteoinductive in an
athymic rat model and has been validated to inactivate a panel of
including: HIV-1, hepatitis B (using a duck hepatitis virus as a model),
hepatitis C (using a bovine diarrhea virus as a model), CMV and polio. 
validated process is used to further reduce the risk of disease
beyond the protection provided by donor testing and screening

    Certain statements made in this press release that are not
facts contain forward-looking statements (as such are defined in the
Securities Litigation Reform Act of 1995) regarding the Company's future
plans, objectives and expected performance.  Any such forward-looking
statements are based on assumptions that the Company believes are
but are subject to a wide range of risks and uncertainties and,
there can be no assurance that the actual results may not differ
from those expressed or implied by such forward-looking statements. 
that could cause actual results to differ materially include, but are
limited to, the failure of the FDA to clear the Company's additional
submissions for its Grafton(R) DBM and private label product lines, the
continued acceptance and growth of current products and services,
in anticipated and actual product and service introduction dates, the
success of those products in their marketplace, the impact of
products and services, the availability of sufficient quantities of
donated tissue and the success of cost control and margin improvement
Certain of these factors are detailed from time to time in the Company's
periodic reports (including the Annual report on Form 10-K for the year
December 31, 2004 and the Form 10-Q for each of the first three
quarters of
2005) filed with the Securities and Exchange Commission.  All
information in
this press release is as of November 28, 2005 and the Company
undertakes no
duty to update this information.

    Osteotech, Inc., headquartered in Eatontown, New Jersey, is a
provider of human bone and bone connective tissue for transplantation
and an
innovator in the development and marketing of biomaterial and implant
for musculoskeletal surgery.  For further information regarding
Osteotech or
this press release, please go to Osteotech's website homepage at
and to Osteotech's Financial Information Request Form
website page at

IsoTis OrthoBiologics Receives FDA 510(k) Clearance for OrthoBlast(R) II Bone Grafting Material

    LAUSANNE, Switzerland, IRVINE, California, December 8
/PRNewswire-FirstCall/ — IsoTis OrthoBiologics (SWX/Euronext:
ISO) today announced it received 510(k) clearance from the US Food and
Administration (FDA) for the use of OrthoBlast II(R) in orthopedic
    IsoTis OrthoBiologics has previously obtained 510(k) clearances for
DynaGraft II(TM), Accell Connexus (TM), OsSatura(TM), and its bone
aspiration kit Aspirex. Accell(R) DBM100 and Accell TBM(TM), having no
excipient carriers, are regulated by the FDA as human tissue and not as
medical devices requiring premarket clearance.
    Pieter Wolters, President and CEO of IsoTis said: “With the 510(k)
clearance of OrthoBlast II, all IsoTis' marketed products are in
with FDA regulations, and we can continue to focus on servicing the
orthopedic profession with products that are first in class in the bone
grafting market. The increased uptake of our innovative Accell product
as a result of the high levels of BMPs it contains, and the solid market
position of first generation products like OrthoBlast II, provide us
with a
healthy basis for growth in the years to come.”
    OrthoBlast II is a combination of demineralized bone matrix (DBM)
cancellous bone chips delivered in a reverse phase medium. The reverse
medium becomes more viscous at body temperature, but less viscous at
temperatures. Therefore, it is malleable at operating room
temperatures, but
thickens when placed in the operative site. This allows the DBM to be
contained at the graft site with minimal loss through irrigation and
    IsoTis OrthoBiologics has a product portfolio with several
innovative and
proprietary natural and synthetic bone graft substitutes on the market
others in development, an established North American independent
network, and an expanding international presence. The company's main
commercial operations are based out of Irvine, CA; its international
headquarters is based in Lausanne, Switzerland.
    Certain statements in this Press Release are “forward-looking
within the meaning of Section 21E of the Securities Exchange Act of
1934, as
amended, including those that refer to management's plans and
for future operations, prospects and financial condition. Words such as
'strategy,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'will,'
'continues,' 'estimates,' 'intends,' 'projects,' 'goals,' 'targets' and
words of similar meaning are intended to identify such forward-looking
statements. One can also identify them by the fact that they do not
strictly to historical or current facts. Such statements are based on
current expectations of the management of IsoTis S.A. only. Undue
should not be placed on these statements because, by their nature, they
subject to known and unknown risks and can be affected by factors that
beyond the control of IsoTis. Actual results could differ materially
current expectations due to a number of factors and uncertainties
IsoTis' business, including but not limited to the timely commencement
success of IsoTis' clinical trials and research endeavors, delays in
receiving U.S. FDA or other regulatory approvals (a.o. EMEA, CE), market
acceptance of the Company's products, development of competing therapies
and/or technologies, the terms of any future strategic alliances, the
for additional capital, the inability to obtain, or meet conditions
for the required governmental and regulatory approvals and consents.
expressly disclaims any intent or obligation to update these
statements except as required by law. For a more detailed description
of the
risk factors and uncertainties affecting IsoTis, refer to the Company's
Annual Report on Form 20-F for the fiscal year ended December 31, 2004,
with the SEC and to IsoTis' reports filed from time to time with the
Stock Exchange (SWX), Euronext Amsterdam N.V., and SEDAR at,
well as the Toronto Stock Exchange (TSX).

SOURCE IsoTis OrthoBiologics

The Vertical Expandable Prosthetic Titanium rib becomes 1st new FDA-approved spine deformity treatment in 40 years

The Vertical Expandable Prosthetic Titanium rib becomes 1st new
FDA-approved spine deformity treatment in 40 years

Posted: Tuesday, September 14, 2004 · Volume:XXXVII· Issue: 37

Contact: Will Sansom
Phone: (210) 567-2570

San Antonio (Sept. 13, 2004) – The Vertical Expandable Prosthetic
Titanium Rib (VEPTR), a device that has saved the lives of 300 infants
and young children who otherwise would have died from lack of breath,
has been approved by the U.S. Food and Drug Administration (FDA). The
inventor from The University of Texas Health Science Center at San
Antonio and the Thoracic Institute at CHRISTUS Santa Rosa Children’s
Hospital said it is the first new growth-sparing spine deformity
treatment to gain FDA approval in more than four decades.

“We have described a new disease and have named it thoracic
insufficiency syndrome,” said Robert M. Campbell Jr., M.D., professor
of orthopedics at the Health Science Center, director of the Thoracic
Institute at CHRISTUS Santa Rosa and inventor of the titanium rib. “It
describes a group of patients who have scoliosis, may have fused ribs
or a small chest, and this causes harm to respiration and lung growth.
Characterizing the disease is more important than the titanium rib
itself, because children with these conditions can be diagnosed more
clearly using the thoracic insufficiency syndrome approach. We expect
more sophisticated and better surgical solutions to be developed in the

The work began in 1987 with the encouragement of Melvin D. Smith, M.D.,
staff physician at the Thoracic Institute and professor of pediatric
general surgery at the Health Science Center. Dr. Smith went to Dr.
Campbell with X-rays of infant Christopher Cardenas, who was born
without a chest wall. The only option to save Christopher was to create
an artificial chest wall, which the doctors were able to accomplish.
Two years later, Dr. Campbell, who began college as an engineering
student, developed the titanium rib and the surgeons were ready to
implant it in a child – 2-year-old Christopher Cardenas. The operation
was a success and Christopher, of San Antonio, now is 17.

The titanium rib is curved like a ribcage and has holes that allow the
surgeons to expand the device in outpatient surgery every six months.
The rib is implanted in infants as young as 6 months and in teenagers
until skeletal maturity, typically age 14 in girls and age 16 in boys.
“Our data suggest the earlier the better,” Dr. Campbell said. “The lung
growth curve is best in the first two years of life.” The rib is made
of titanium, a material that is lightweight, compatible with body
tissues and does not interfere with MRI scans.

“We are starting to see several ‘Rib’ kids reach skeletal maturity,”
Dr. Campbell added. “If the devices are performing their function and
not causing a problem, we leave them in. It’s case by case, and there
is not a global answer as to when to remove the device.”

As with any surgery, there is the potential for infection, but the
surgeons have found the infection rate to be no different than for
other types of surgeries. “There is a chance of devices drifting into
the bone, and there can be skin problems over the rib if the kids do
not have enough body weight, but we believe what it does to help the
children outweighs the risks,” Dr. Campbell said.

Drs. Campbell and Smith have developed five new operations utilizing
the titanium rib and have described thoracic insufficiency syndrome in
four landmark papers in orthopedics journals. The surgeons have taught
the titanium rib surgery techniques to other tertiary pediatric
hospitals throughout the United States and all over the world. Last
week, Drs. Campbell and Smith returned from a trip to a children’s
hospital in Buenos Aires, Argentina. Last month, Dr. Campbell performed
the surgery at Birmingham Children’s Hospital in England.

Dr. Campbell did the research in private practice for several years,
but needed the support of an academic health science university for the
project to proceed. He joined the Health Science Center faculty in
1992. “The Health Science Center has provided support for this research
and helped make it happen,” Dr. Campbell said. “CHRISTUS Santa Rosa has
been the site of all the titanium rib surgeries here in San Antonio.”
In the mid-1990s, Drs. Campbell and Smith, the Health Science Center
and CHRISTUS Santa Rosa became coordinators of a multicenter FDA
clinical trial to test the titanium rib. About 210 children have had
the surgery at CHRISTUS Santa Rosa, and 90 at seven other children’s
hospitals in Pittsburgh, Boston, Salt Lake City, Los Angeles, Seattle
and Philadelphia.

“It took 13 years to gain FDA approval because it took a long time to
accumulate a lot of patients with rare diseases,” Dr. Campbell said.
“Also, the FDA examines very carefully any new spine treatment,
especially one that is for children.”

The last major advance in spine treatment came along in 1962 – the
Harrington Rod developed by Dr. Paul Harrington of Houston. The device
revolutionized spine surgery, Dr. Campbell said.

For Frequently Asked Questions about the VEPTR visit:

For the chronology of the Titanium Rib Project, visit:

For information about the Katka's twins visit:

OsteoBiologics, Inc. Receives 510(k) Clearance From FDA to Market and Distribute its PolyGraft(TM) TCP Bone Graft Substitute

OsteoBiologics, Inc. Receives 510(k) Clearance From
FDA to Market and Distribute its PolyGraft(TM) TCP Bone Graft Substitute


    SAN ANTONIO, Aug. 30 /PRNewswire/ -- OsteoBiologics, Inc. ("OBI"), an
innovator in tissue repair technologies, announced that it has received 510(k)
Premarket Notification from the Food and Drug Administration to market and
distribute its newest formulation of composite bone void filler device called
PolyGraft(TM) TCP Bone Graft Substitute.  The porous PolyGraft(TM) TCP
material is composed of a patented blend of polylactide-co-glycolide,
tricalcium phosphate and polyglycolide fibers.  The PolyGraft(TM) TCP material
can be fabricated into products such as granules, blocks, wedges and other
preformed shapes and is indicated to be used to fill bony voids or gaps caused
by trauma or surgery that are not intrinsic to the stability of the bony
structure.  The PolyGraft(TM) TCP is intended to be gently packed into bony
voids or gaps of the skeletal system (i.e., the extremities, spine and
pelvis), and these defects may be surgically created osseous defects or bone
defects due to traumatic injury to the bone.  "OBI has developed another
composite bone void filler in which the ceramic portion resorbs slower to
enhance strength retention," stated Fred Dinger, President and CEO of OBI.
"The availability of this technology platform gives OBI the opportunity to
continue our rapid product line expansion and enables us to provide solutions
for the body to heal itself for a broader range of unmet clinical needs."
About OsteoBiologics, Inc.
    OBI, located in San Antonio, Texas, is a private company that develops and
manufactures bioabsorbable polymeric scaffolds, films, and related
instrumentation for the repair and replacement of bone, soft tissue and
cartilage.  Its products are based on proprietary and patented technologies
covered by U.S. and foreign patents.  The Company is focusing on
commercializing and further developing its platform technologies in
arthroscopy and sports medicine.  Additionally, OBI is actively forming
strategic alliances with companies serving other areas of medicine such as
spine, trauma, general orthopedics, and wound care to leverage its
technologies into those markets.
    Certain statements made in this press release are forward looking
statements as such term is defined in the Private Securities litigation Reform
Act of 1995.
    For more information, please contact Daniel Lee, Director of Marketing at
(210) 690-2131.

SOURCE OsteoBiologics, Inc.
Web Site:

Wright Medical Group, Inc. Receives FDA Clearances for the Entire Family of ALLOMATRIX Products

    ARLINGTON, Tenn.--(BUSINESS WIRE)--July 15, 2004--

Notification Completes Clearance for Products Currently In Wright's
ALLOMATRIX(R) Line of Allograft Bone Void Fillers

Wright Medical Group, Inc. (NASDAQ:WMGI), a global orthopaedic
medical device company specializing in the design, manufacture and
marketing of reconstructive joint devices and biologic materials,
today announced receipt of marketing clearance from the United States
Food and Drug Administration (FDA) for ALLOMATRIX(R) C, ALLOMATRIX(R)
Custom, and ALLOMATRIX(R) DR bone graft putties that contain
demineralized bone matrix (DBM) and specific volumes and
configurations of donor matched, cancellous bone chips. Following the
FDA-clearance of ALLOMATRIX(R) Injectable Putty in March of this year,
today's regulatory announcement completes the clearance process for
Wright's entire ALLOMATRIX(R) family of products.

The Company began the 510(k) premarket notification process in
March of 2002, following FDA's clarification to all allograft putty
providers that such products are considered medical devices and are
therefore regulated under the federal Food, Drug, and Cosmetic Act.
The Company has satisfied FDA's medical device requirements for
demonstrating substantial equivalence, including endpoints established
for each product's clinical performance and viral inactivation
potential. The ALLOMATRIX(R) family of products and OSTEOSET(R) 2 DBM
are the only commercially available, FDA-cleared products which
contain demineralized bone matrix (DBM).

Laurence Fairey, President and Chief Executive Officer, commented,
“Wright Medical has demonstrated a successful strategy of using these
specialized formulations to address individual clinical needs targeted
at individual orthopaedic sub-specialties. Wright's ability to
understand and address specific surgical requirements by developing
these focused products reinforces the Company's growing reputation for
its comprehensive understanding and responsiveness to the expanding
bio-orthopaedic market.”

About Wright

Wright Medical Group, Inc. is a global orthopaedic medical device
company specializing in the design, manufacture and marketing of
reconstructive joint devices and biologic materials. The Company has
been in business for more than 50 years and markets its products in
over 40 countries worldwide. For more information about Wright, visit
our website at

This press release may contain “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements made in this press release, other than statements of
historical fact, are forward-looking statements. Forward-looking
statements reflect management's current knowledge, assumptions,
beliefs, estimates, and expectations and express management's current
views of future performance, results, and trends. The Company wishes
to caution readers that actual results might differ materially from
those described in the forward-looking statements. Forward-looking
statements are subject to a number of risks and uncertainties,
including the factors discussed in the Company's filings with the
Securities and Exchange Commission (including the Company's annual
report on Form 10-K for the year ended December 31, 2003), which could
cause the Company's actual results to materially differ from those
described in the forward-looking statements. Although the Company
believes that the forward-looking statements are accurate, there can
be no assurance that any forward-looking statement will prove to be
accurate. A forward-looking statement should not be regarded as a
representation by the Company that the results described therein will
be achieved. The Company wishes to caution readers not to place undue
reliance on any forward-looking statement. The forward-looking
statements are made as of the date of this press release. The Company
assumes no obligation to update any forward-looking statement after
this date.

    CONTACT: Wright Medical Group Inc., Arlington

John K. Bakewell, 901-867-4527

SOURCE: Wright Medical Group, Inc.

Harbor” Statement under the Private Securities Litigation Reform Act of
1995: Statements in this press release regarding Wright Medical Group,
Inc.'s business which are not historical facts are “forward-looking
statements” that involve risks and uncertainties. For a discussion of
such risks and uncertainties, which could cause actual results to
differ from those contained in the forward-looking statements, see
“Risk Factors” in the Company's Annual Report or Form 10-K for the most
recently ended fiscal year.